

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER: 09/076,404
FILING DATE: 05/12/1998
FIRST NAMED INVENTOR: David J. Ecker
ART UNIT: 1631
EXAMINER NAME: John S. Brusca
CONFIRMATION NUMBER: 4802
ATTORNEY DOCKET NUMBER: IBIS-0007US
TITLE: MODULATION OF MOLECULAR
INTERACTION SITES ON RNA AND
OTHER BIOMOLECULES

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
Under 37 C.F.R. §§ 1.56 and 1.97-98


SIR:

Pursuant to the provisions of 37 C.F. R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Forms PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner. Copies of all references required to be provided are also enclosed.

This Information Disclosure Statement is being filed before the mailing of a first official action after filing of a request for continued examination (RCE) under 37 C.F.R. § 1.114; therefore, it is believed that no fee is due.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

Respectfully submitted,



Frances R. Putkey, Ph.D.
Registration No.: 57,257
Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad, CA 92008

Dated: January 3, 2008